Trial Profile
Exacerbation Profile in Patients on Mepolizumab for Severe Refractory Eosinophilic Asthma- an Exploratory Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 09 Jul 2019 Status changed from recruiting to completed.
- 12 Apr 2018 Status changed from not yet recruiting to recruiting.
- 01 Nov 2017 New trial record